Clinical Trial Update: An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated crizotinib (PF-02341066) versus standard of care in advanced ALK-positive non-small cell lung cancer; the study is completed and resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2013-06-06